Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 14 Researches
8.2
USERS' SCORE
Good
Based on 5 Reviews
8.5
Supplement Facts
Serving Size: 1 Capsule
Amount Per Serving
%DV
Turmeric ExtractCurcuma longa (Rhizome)(95% [475 mg] Total Curcuminoids)
500 mg
†
Top Medical Research Studies
9
We explored the impact of curcumin, a natural compound found in turmeric, on non-small cell lung cancer (NSCLC). Our investigation utilized two models: laboratory-based NSCLC cell lines (A549 and NCI-H1299) and a mouse tumor model. By applying curcumin treatment, we aimed to understand how it influences cell growth and induces a specific form of cell death known as pyroptosis.
Our findings revealed that curcumin effectively slowed down the growth of NSCLC cells and triggered pyroptosis. This process is mediated through interactions with a protein called Smurf2, which regulates the ubiquitination of another protein, NLRP3. We observed that when Smurf2 activity was inhibited by curcumin, NLRP3 was stabilized, leading to increased levels of pyroptosis-associated factors.
In the animal study, curcumin treatment also resulted in smaller tumor sizes and decreased expression of Ki67, a marker for cell proliferation. Furthermore, this treatment increased NLRP3 and the factors linked to pyroptosis. Overall, our work illustrates how curcumin may hold therapeutic promise for lung cancer treatment by promoting destruction of cancer cells through pyroptosis.
Our findings revealed that curcumin effectively slowed down the growth of NSCLC cells and triggered pyroptosis. This process is mediated through interactions with a protein called Smurf2, which regulates the ubiquitination of another protein, NLRP3. We observed that when Smurf2 activity was inhibited by curcumin, NLRP3 was stabilized, leading to increased levels of pyroptosis-associated factors.
In the animal study, curcumin treatment also resulted in smaller tumor sizes and decreased expression of Ki67, a marker for cell proliferation. Furthermore, this treatment increased NLRP3 and the factors linked to pyroptosis. Overall, our work illustrates how curcumin may hold therapeutic promise for lung cancer treatment by promoting destruction of cancer cells through pyroptosis.
Read More
8
We explored how curcumin, a compound derived from turmeric, can be used to combat multidrug-resistant lung cancer through inhalation therapy. In our study, we focused on comparing small (30 nm) and larger (200 nm) nanoparticles of curcumin, nebulized to target resistant cancer cells known as H69AR.
Our findings revealed that the smaller curcumin nanoparticles led to significantly higher cell death in these lung cancer cells. This heightened effectiveness is attributed to their improved uptake into the cells, primarily through a specific cellular process known as dynamin-dependent clathrin-mediated endocytosis.
We further discovered that the smaller nanoparticles not only reached the desired cancer cells more effectively, but also triggered higher oxidative stress, resulting in greater mitochondrial dysfunction. The study also highlighted a reduction in a protein associated with drug resistance, suggesting that these curcumin nanoparticles could help in overcoming the resistance displayed by these cancer cells.
Overall, our research indicates that nebulized small curcumin nanoparticles hold promise for treating difficult lung cancers, showing a significant potential impact on how we approach targeted therapies for such conditions.
Our findings revealed that the smaller curcumin nanoparticles led to significantly higher cell death in these lung cancer cells. This heightened effectiveness is attributed to their improved uptake into the cells, primarily through a specific cellular process known as dynamin-dependent clathrin-mediated endocytosis.
We further discovered that the smaller nanoparticles not only reached the desired cancer cells more effectively, but also triggered higher oxidative stress, resulting in greater mitochondrial dysfunction. The study also highlighted a reduction in a protein associated with drug resistance, suggesting that these curcumin nanoparticles could help in overcoming the resistance displayed by these cancer cells.
Overall, our research indicates that nebulized small curcumin nanoparticles hold promise for treating difficult lung cancers, showing a significant potential impact on how we approach targeted therapies for such conditions.
Read More
9
We explored the potential of curcumin, a compound found in turmeric, as a treatment for non-small cell lung cancer (NSCLC) by utilizing camel milk-derived exosomes as delivery vehicles. Traditional treatments for lung cancer often face challenges, including side effects and drug resistance, prompting the search for more effective solutions.
The study involved isolating exosomes from camel milk and confirming their properties through various tests. We found that these exosomes could effectively encapsulate curcumin, achieving a 20% loading efficiency. When we tested the exosomal formulation of curcumin, known as ExoCUR, we observed a significant increase in cytotoxic effects against both sensitive and resistant lung cancer cells compared to free curcumin.
Moreover, our molecular studies indicated that curcumin interacts strongly with the epidermal growth factor receptor (EGFR), a key player in cancer progression. This interaction suggests that curcumin can interfere with vital cancer signaling pathways. Overall, our findings demonstrate that camel milk-derived exosomes offer a promising method for enhancing the delivery and effectiveness of curcumin, potentially overcoming some limitations of current cancer therapies.
The study involved isolating exosomes from camel milk and confirming their properties through various tests. We found that these exosomes could effectively encapsulate curcumin, achieving a 20% loading efficiency. When we tested the exosomal formulation of curcumin, known as ExoCUR, we observed a significant increase in cytotoxic effects against both sensitive and resistant lung cancer cells compared to free curcumin.
Moreover, our molecular studies indicated that curcumin interacts strongly with the epidermal growth factor receptor (EGFR), a key player in cancer progression. This interaction suggests that curcumin can interfere with vital cancer signaling pathways. Overall, our findings demonstrate that camel milk-derived exosomes offer a promising method for enhancing the delivery and effectiveness of curcumin, potentially overcoming some limitations of current cancer therapies.
Read More
Most Useful Reviews
9
In remission
103 people found this helpful
Elizabeth B: Curcumin is known for its anti-cancer properties. I have been taking 2g (4 capsules) daily since shortly after my stage 4 lung cancer diagnosis a year ago. I went into remission within three months, and all my tumours have since disappeared. I have been in remission with no evidence of disease for eight months now.
Read More
7.5
Supports treatment
Antinflammatory properties: I appreciate how effective curcumin is. It really helps with my joints and cartilage while I undergo lung cancer therapy.
Read More
7.5
Reduced inflammation
Inflammation has reduced! Known for its anti-cancer and anti-inflammatory properties, this brand is quite good for lung cancer treatment!
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 14 Researches
8.2
- All Researches
9
We explored the potential of a curcumin derivative, CU17, in enhancing the effectiveness of Gemcitabine (Gem) against lung cancer. The study examined how this combination therapy affects A549 non-small-cell lung cancer (NSCLC) cells in laboratory settings and in mouse models.
Our findings revealed that CU17 significantly increased the anti-cancer strength of Gem, leading to better control over cancer cell survival. This was achieved by prolonging the S phase of the cell cycle and inducing G2/M phase arrest, which involved proteins like p21 and p53. Furthermore, CU17 boosted the apoptotic effects of Gem by altering the balance of pro-apoptotic and anti-apoptotic factors.
Additionally, in the in vivo experiments, CU17 not only enhanced the anti-cancer effects of Gem but also reduced its toxicity to vital organs such as the liver, kidneys, and spleen. Overall, our research highlights CU17 as a promising chemosensitizer that could improve treatment outcomes for patients with NSCLC without significantly increasing the side effects of Gem.
Our findings revealed that CU17 significantly increased the anti-cancer strength of Gem, leading to better control over cancer cell survival. This was achieved by prolonging the S phase of the cell cycle and inducing G2/M phase arrest, which involved proteins like p21 and p53. Furthermore, CU17 boosted the apoptotic effects of Gem by altering the balance of pro-apoptotic and anti-apoptotic factors.
Additionally, in the in vivo experiments, CU17 not only enhanced the anti-cancer effects of Gem but also reduced its toxicity to vital organs such as the liver, kidneys, and spleen. Overall, our research highlights CU17 as a promising chemosensitizer that could improve treatment outcomes for patients with NSCLC without significantly increasing the side effects of Gem.
Read More
9
We explored the impact of curcumin, a natural compound found in turmeric, on non-small cell lung cancer (NSCLC). Our investigation utilized two models: laboratory-based NSCLC cell lines (A549 and NCI-H1299) and a mouse tumor model. By applying curcumin treatment, we aimed to understand how it influences cell growth and induces a specific form of cell death known as pyroptosis.
Our findings revealed that curcumin effectively slowed down the growth of NSCLC cells and triggered pyroptosis. This process is mediated through interactions with a protein called Smurf2, which regulates the ubiquitination of another protein, NLRP3. We observed that when Smurf2 activity was inhibited by curcumin, NLRP3 was stabilized, leading to increased levels of pyroptosis-associated factors.
In the animal study, curcumin treatment also resulted in smaller tumor sizes and decreased expression of Ki67, a marker for cell proliferation. Furthermore, this treatment increased NLRP3 and the factors linked to pyroptosis. Overall, our work illustrates how curcumin may hold therapeutic promise for lung cancer treatment by promoting destruction of cancer cells through pyroptosis.
Our findings revealed that curcumin effectively slowed down the growth of NSCLC cells and triggered pyroptosis. This process is mediated through interactions with a protein called Smurf2, which regulates the ubiquitination of another protein, NLRP3. We observed that when Smurf2 activity was inhibited by curcumin, NLRP3 was stabilized, leading to increased levels of pyroptosis-associated factors.
In the animal study, curcumin treatment also resulted in smaller tumor sizes and decreased expression of Ki67, a marker for cell proliferation. Furthermore, this treatment increased NLRP3 and the factors linked to pyroptosis. Overall, our work illustrates how curcumin may hold therapeutic promise for lung cancer treatment by promoting destruction of cancer cells through pyroptosis.
Read More
9
We explored the potential of curcumin, a compound found in turmeric, as a treatment for non-small cell lung cancer (NSCLC) by utilizing camel milk-derived exosomes as delivery vehicles. Traditional treatments for lung cancer often face challenges, including side effects and drug resistance, prompting the search for more effective solutions.
The study involved isolating exosomes from camel milk and confirming their properties through various tests. We found that these exosomes could effectively encapsulate curcumin, achieving a 20% loading efficiency. When we tested the exosomal formulation of curcumin, known as ExoCUR, we observed a significant increase in cytotoxic effects against both sensitive and resistant lung cancer cells compared to free curcumin.
Moreover, our molecular studies indicated that curcumin interacts strongly with the epidermal growth factor receptor (EGFR), a key player in cancer progression. This interaction suggests that curcumin can interfere with vital cancer signaling pathways. Overall, our findings demonstrate that camel milk-derived exosomes offer a promising method for enhancing the delivery and effectiveness of curcumin, potentially overcoming some limitations of current cancer therapies.
The study involved isolating exosomes from camel milk and confirming their properties through various tests. We found that these exosomes could effectively encapsulate curcumin, achieving a 20% loading efficiency. When we tested the exosomal formulation of curcumin, known as ExoCUR, we observed a significant increase in cytotoxic effects against both sensitive and resistant lung cancer cells compared to free curcumin.
Moreover, our molecular studies indicated that curcumin interacts strongly with the epidermal growth factor receptor (EGFR), a key player in cancer progression. This interaction suggests that curcumin can interfere with vital cancer signaling pathways. Overall, our findings demonstrate that camel milk-derived exosomes offer a promising method for enhancing the delivery and effectiveness of curcumin, potentially overcoming some limitations of current cancer therapies.
Read More
9
Our investigation focused on the structural characteristics and potential cancer-fighting abilities of a specific polysaccharide derived from turmeric, identified as TPE-I. We observed that TPE-I has a distinct structure similar to a well-known type of pectin called rhamnogalacturonan-I (RG-I).
Through our experiments, we found that TPE-I not only affected the immune response but also showed promising anti-cancer effects specifically against lung cancer. Notably, when we administered TPE-I, it enhanced the capacity of important immune cells, like natural killer (NK) cells and cytotoxic T lymphocytes, to attack tumor cells effectively.
Interestingly, even when we blocked NK cell function in mice, the positive effects of TPE-I in inhibiting lung cancer continued. This suggests that TPE-I operates through mechanisms beyond just NK cell activity. Our findings highlight that turmeric contains not only curcuminoids—commonly known for their health benefits—but also other bioactive compounds that might play crucial roles in cancer treatment.
Through our experiments, we found that TPE-I not only affected the immune response but also showed promising anti-cancer effects specifically against lung cancer. Notably, when we administered TPE-I, it enhanced the capacity of important immune cells, like natural killer (NK) cells and cytotoxic T lymphocytes, to attack tumor cells effectively.
Interestingly, even when we blocked NK cell function in mice, the positive effects of TPE-I in inhibiting lung cancer continued. This suggests that TPE-I operates through mechanisms beyond just NK cell activity. Our findings highlight that turmeric contains not only curcuminoids—commonly known for their health benefits—but also other bioactive compounds that might play crucial roles in cancer treatment.
Read More
9
This study explored the potential of curcumin, a natural compound from turmeric, as a treatment for lung cancer, particularly focusing on non-small cell lung cancer (NSCLC). We examined how curcumin-loaded liposomes, specifically the formulation called PlexoZome®, affect A549 human lung adenocarcinoma cells.
Our findings were quite promising. The use of liposomal curcumin significantly reduced the proliferation and migration of these cancer cells. We also noted a marked decrease in the expression of several cancer marker proteins, which suggests that this treatment could hinder cancer development and spread.
The encapsulation of curcumin in liposomes appears to enhance its effectiveness, potentially addressing the issue of poor solubility and bioavailability commonly associated with curcumin. This research paves the way for developing a novel therapeutic option for patients battling NSCLC, highlighting curcumin's role as a valuable phytochemical in cancer treatment.
Our findings were quite promising. The use of liposomal curcumin significantly reduced the proliferation and migration of these cancer cells. We also noted a marked decrease in the expression of several cancer marker proteins, which suggests that this treatment could hinder cancer development and spread.
The encapsulation of curcumin in liposomes appears to enhance its effectiveness, potentially addressing the issue of poor solubility and bioavailability commonly associated with curcumin. This research paves the way for developing a novel therapeutic option for patients battling NSCLC, highlighting curcumin's role as a valuable phytochemical in cancer treatment.
Read More
User Reviews
USERS' SCORE
Good
Based on 5 Reviews
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
9
In remission
103 people found this helpful
Elizabeth B: Curcumin is known for its anti-cancer properties. I have been taking 2g (4 capsules) daily since shortly after my stage 4 lung cancer diagnosis a year ago. I went into remission within three months, and all my tumours have since disappeared. I have been in remission with no evidence of disease for eight months now.
Read More
7.5
Supports treatment
Antinflammatory properties: I appreciate how effective curcumin is. It really helps with my joints and cartilage while I undergo lung cancer therapy.
Read More
7.5
Reduced inflammation
Inflammation has reduced! Known for its anti-cancer and anti-inflammatory properties, this brand is quite good for lung cancer treatment!
Read More
6
May prevent cancer
1 people found this helpful
Regular consumption of curcumin, as an antioxidant, may help prevent lung cancer.
Read More
4
No noticeable effect
I bought it because curcumin is said to be beneficial for lung cancer and immunity, but I haven’t noticed any effect, so I won't purchase it again.
Read More
Frequently Asked Questions
9
In remission
103 people found this helpful
Elizabeth B: Curcumin is known for its anti-cancer properties. I have been taking 2g (4 capsules) daily since shortly after my stage 4 lung cancer diagnosis a year ago. I went into remission within three months, and all my tumours have since disappeared. I have been in remission with no evidence of disease for eight months now.
4
No noticeable effect
I bought it because curcumin is said to be beneficial for lung cancer and immunity, but I haven’t noticed any effect, so I won't purchase it again.
7.5
Supports treatment
Antinflammatory properties: I appreciate how effective curcumin is. It really helps with my joints and cartilage while I undergo lung cancer therapy.
7.5
Reduced inflammation
Inflammation has reduced! Known for its anti-cancer and anti-inflammatory properties, this brand is quite good for lung cancer treatment!
9
We explored the potential of a curcumin derivative, CU17, in enhancing the effectiveness of Gemcitabine (Gem) against lung cancer. The study examined how this combination therapy affects A549 non-small-cell lung cancer (NSCLC) cells in laboratory settings and in mouse models.
Our findings revealed that CU17 significantly increased the anti-cancer strength of Gem, leading to better control over cancer cell survival. This was achieved by prolonging the S phase of the cell cycle and inducing G2/M phase arrest, which involved proteins like p21 and p53. Furthermore, CU17 boosted the apoptotic effects of Gem by altering the balance of pro-apoptotic and anti-apoptotic factors.
Additionally, in the in vivo experiments, CU17 not only enhanced the anti-cancer effects of Gem but also reduced its toxicity to vital organs such as the liver, kidneys, and spleen. Overall, our research highlights CU17 as a promising chemosensitizer that could improve treatment outcomes for patients with NSCLC without significantly increasing the side effects of Gem.
Our findings revealed that CU17 significantly increased the anti-cancer strength of Gem, leading to better control over cancer cell survival. This was achieved by prolonging the S phase of the cell cycle and inducing G2/M phase arrest, which involved proteins like p21 and p53. Furthermore, CU17 boosted the apoptotic effects of Gem by altering the balance of pro-apoptotic and anti-apoptotic factors.
Additionally, in the in vivo experiments, CU17 not only enhanced the anti-cancer effects of Gem but also reduced its toxicity to vital organs such as the liver, kidneys, and spleen. Overall, our research highlights CU17 as a promising chemosensitizer that could improve treatment outcomes for patients with NSCLC without significantly increasing the side effects of Gem.
9
We explored the impact of curcumin, a natural compound found in turmeric, on non-small cell lung cancer (NSCLC). Our investigation utilized two models: laboratory-based NSCLC cell lines (A549 and NCI-H1299) and a mouse tumor model. By applying curcumin treatment, we aimed to understand how it influences cell growth and induces a specific form of cell death known as pyroptosis.
Our findings revealed that curcumin effectively slowed down the growth of NSCLC cells and triggered pyroptosis. This process is mediated through interactions with a protein called Smurf2, which regulates the ubiquitination of another protein, NLRP3. We observed that when Smurf2 activity was inhibited by curcumin, NLRP3 was stabilized, leading to increased levels of pyroptosis-associated factors.
In the animal study, curcumin treatment also resulted in smaller tumor sizes and decreased expression of Ki67, a marker for cell proliferation. Furthermore, this treatment increased NLRP3 and the factors linked to pyroptosis. Overall, our work illustrates how curcumin may hold therapeutic promise for lung cancer treatment by promoting destruction of cancer cells through pyroptosis.
Our findings revealed that curcumin effectively slowed down the growth of NSCLC cells and triggered pyroptosis. This process is mediated through interactions with a protein called Smurf2, which regulates the ubiquitination of another protein, NLRP3. We observed that when Smurf2 activity was inhibited by curcumin, NLRP3 was stabilized, leading to increased levels of pyroptosis-associated factors.
In the animal study, curcumin treatment also resulted in smaller tumor sizes and decreased expression of Ki67, a marker for cell proliferation. Furthermore, this treatment increased NLRP3 and the factors linked to pyroptosis. Overall, our work illustrates how curcumin may hold therapeutic promise for lung cancer treatment by promoting destruction of cancer cells through pyroptosis.
7
We focused on the potential of curcumin, a compound found in turmeric, in treating lung cancer, specifically by utilizing advanced drug delivery through liposomes. Our investigation zeroed in on curcumin-loaded PlexoZome® (CUR-PLXZ) to determine its effects on critical biomarkers in lung cancer management.
The study emphasized the roles of EpCAM/TROP1 and estrogen receptor alpha (ERα), both of which are often overexpressed in lung cancer and linked to tumor growth and metastatic spread. By testing CUR-PLXZ on the A549 lung adenocarcinoma cell line, we discovered that this formulation effectively inhibited the expression of both EpCAM and ERα at a concentration of 5 μM.
This result is significant as it suggests that curcumin, particularly when delivered through liposomes, may offer a targeted approach to impacting these important pathways in lung cancer. Therefore, our findings pave the way for further exploration into curcumin-based therapies in managing this disease.
The study emphasized the roles of EpCAM/TROP1 and estrogen receptor alpha (ERα), both of which are often overexpressed in lung cancer and linked to tumor growth and metastatic spread. By testing CUR-PLXZ on the A549 lung adenocarcinoma cell line, we discovered that this formulation effectively inhibited the expression of both EpCAM and ERα at a concentration of 5 μM.
This result is significant as it suggests that curcumin, particularly when delivered through liposomes, may offer a targeted approach to impacting these important pathways in lung cancer. Therefore, our findings pave the way for further exploration into curcumin-based therapies in managing this disease.
9
We explored the potential of curcumin, a natural compound derived from turmeric, alongside baicalin as a treatment for non-small cell lung cancer (NSCLC). In our study, we developed a nanoliposome system specifically designed for co-delivery of these compounds, using a method called thin-film hydration.
During our experiments, we observed that this nanoliposome formulation, termed Lip-Cur/Ba, showed a strong ability to kill A549 cancer cells. In fact, the effectiveness of Lip-Cur/Ba was reported to be 67.8% and 51.9% greater than each compound used separately. This suggests that combining these two natural agents might enhance their therapeutic impact, potentially allowing for reduced dosages and better drug release profiles.
We also conducted in vivo tests on mice and found promising anti-tumor effects without significant toxicity. These findings provide an exciting perspective on using turmeric, in the form of curcumin, alongside baicalin in the therapeutic strategy for lung cancer, paving the way for further research into natural product-based cancer treatments.
During our experiments, we observed that this nanoliposome formulation, termed Lip-Cur/Ba, showed a strong ability to kill A549 cancer cells. In fact, the effectiveness of Lip-Cur/Ba was reported to be 67.8% and 51.9% greater than each compound used separately. This suggests that combining these two natural agents might enhance their therapeutic impact, potentially allowing for reduced dosages and better drug release profiles.
We also conducted in vivo tests on mice and found promising anti-tumor effects without significant toxicity. These findings provide an exciting perspective on using turmeric, in the form of curcumin, alongside baicalin in the therapeutic strategy for lung cancer, paving the way for further research into natural product-based cancer treatments.
References
- Namwan N, Senawong G, Phaosiri C, Kumboonma P, Somsakeesit LO, et al. Synergistic Anti-Cancer Activities of Curcumin Derivative CU17 Combined with Gemcitabine Against A549 Non-Small-Cell Lung Cancer Cells. Pharmaceutics. 2025;17. doi:10.3390/pharmaceutics17020158
- Xi Y, Zeng S, Tan X, Deng X. Curcumin inhibits the activity of ubiquitin ligase Smurf2 to promote NLRP3‑dependent pyroptosis in non‑small cell lung cancer cells. Int J Oncol. 2025;66. doi:10.3892/ijo.2025.5727
- Loo CY, Traini D, Young PM, Yeung S, Leong CR, et al. Evaluation of curcumin nanoparticles of various sizes for targeting multidrug-resistant lung cancer cells via inhalation. Nanomedicine (Lond). 2025;20:141. doi:10.1080/17435889.2024.2439241
- Quek YW, Kang YT, Huang HC, Chang HY, Huang IC, et al. PM induces lung inflammation through ANGPTL4. Mutat Res. 2024;829:111887. doi:10.1016/j.mrfmmm.2024.111887
- Saeed M, Alshagdali K, Moholkar DN, Kandimalla R, Adnan Kausar M, et al. Camel milk-derived exosomes as novel nanocarriers for curcumin delivery in lung cancer. Biomol Biomed. 2024. doi:10.17305/bb.2024.11267
- Choi EH, Son SU, Shin KS. Structural characterization of rhamnogalacturonan-I purified from and its anti-lung cancer efficacy via immunostimulation. Food Sci Biotechnol. 2024;33:3591. doi:10.1007/s10068-024-01595-z
- Kokkinis S, Paudel KR, De Rubis G, Yeung S, Singh M, et al. Liposomal encapsulated curcumin attenuates lung cancer proliferation, migration, and induces apoptosis. Heliyon. 2024;10:e38409. doi:10.1016/j.heliyon.2024.e38409
- Li J, Zhang Z, Zhao J, Liu S, Feng C, et al. Decoding potential targets and pharmacologic mechanisms of curcumin in treating non-small cell lung carcinoma via bioinformatics and molecular docking. Braz J Med Biol Res. 2024;57:e13550. doi:10.1590/1414-431X2024e13550
- Su Q, Pan J, Wang C, Zhang M, Cui H, et al. Curcumin and Baicalin Co-Loaded Nanoliposomes for Synergistic Treatment of Non-Small Cell Lung Cancer. Pharmaceutics. 2024;16. doi:10.3390/pharmaceutics16080973
- Qin X, Wang P, Liang H, Si W. Curcumin suppresses copper accumulation in non-small cell lung cancer by binding ATOX1. BMC Pharmacol Toxicol. 2024;25:54. doi:10.1186/s40360-024-00784-0
- Qasim Almajidi Y, Jawad AQ, Abdulameer Albadri A. Biocompatible PAMAM-PLGA-PCL Nanocarrier for Efficient Curcumin Delivery to Lung Cancer Cells: In Vitro Studies. Chem Biodivers. 2024;21:e202401106. doi:10.1002/cbdv.202401106
- Cho HK, Park CG, Lim HB. Construction of a Synergy Combination Model for Turmeric ( L.) and Black Pepper ( L.) Extracts: Enhanced Anticancer Activity against A549 and NCI-H292 Human Lung Cancer Cells. Curr Issues Mol Biol. 2024;46:5551. doi:10.3390/cimb46060332
- Xu B, Zhou L, Zhang Q. Curcumin Inhibits the Progression of Non-small Cell Lung Cancer by Regulating DMRT3/SLC7A11 Axis. Mol Biotechnol. 2024. doi:10.1007/s12033-024-01166-x
- Singh M, De Rubis G, Kokkinis S, Paudel KR, Yeung S, et al. Curcumin-loaded liposomes modulating the synergistic role of EpCAM and estrogen receptor alpha in lung cancer management. Pathol Res Pract. 2024;257:155317. doi:10.1016/j.prp.2024.155317
